Abstract: Objective To investigate the clinical efficacy of interferon alfa-1b combined with entecavir（ETV）in treatment of patients with chronic hepatitis B（CHB） and high serum viral loads. Methods 92 patients with CHB and high serum viral load （HBV DNA≥1×10⁷ IU/ml） were divided into observation group （n=48） and control group（n=44）. Patients in the control group were treated with interferon alfa-1b,and patients in the observation group were treated with interferon alfa-1b combined with ETV. The treatment course in two groups lasted for 48 weeks. The recovery rates of serum alanine aminotransferase（ALT）,rates of serum HBV DNA loss, negative rates of HBeAg and the conversion rates of HBeAg to anti-HBe were compared at 12,24 and 48 weeks. Serum HBV markers and HBV DNA levels were routinely detected. Results The recovery rates of serum ALT at week 24 and 48 in observation group were 68.8% and 91.7%,respectively,significantly higher than those in the control group（34.1% and 63.6%,P<0.01）;The negative rates of serum HBV DNA at week 12,24 and 48 in the observation group were 45.8%,72.9% and 87.5%,respectively,which were significantly higher than those in the control group（11.4%,31.8% and 47.7%,P<0.01）;The negative rate of HBeAg and the conversion rate of serum HBeAg at the end of week 48 in the observation group were 67.6% and 62.2%,significantly higher than those in the control group（42.9% and 37.1%,P<0.05）. Conclusion Efficacy of interferon alfa-1b combined with ETV in treatment of patients with CHB and high serum viral load is superior to IFN alfa-1b monotherapy.

Key words: Chronic hepatitis B, Interferon alfa-1b, Entecavir, Serum viral loads, Therapeutic efficacy